Floatz logo

Rndo-564

Gastroesophageal Junction (GEJ) Adenocarcinoma

Rondo TherapeuticsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

112 Active assets in the Gastroesophageal Junction (GEJ) Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Rndo-564 is also rated in:

esophageal squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →